| Author | Papot, Emmanuelle | |
| Author | Tovar-Sanchezb, Tamara | |
| Author | Woodsc, Joana | |
| Author | Thaurignac, Guillaume | |
| Author | Eriobu, Nnakelu | |
| Author | Borok, Margaret | |
| Author | Kaplan, Richard | |
| Author | Avihingsanon, Anchalee | |
| Author | Azwa, Iskandar | |
| Author | Grinsztejng, Beatriz | |
| Author | Kumarasamyj, Nagalingeswaran | |
| Author | Sokhela, Simiso | |
| Author | Mpoudi-Etame, Mireille | |
| Author | Arriaga, Maria | |
| Author | Jacoby, Simone | |
| Author | Matthews, Gail V. | |
| Author | Losso, Marcelo H. | |
| Author | Khoo, Saye | |
| Author | Calmy, Alexandra | |
| Author | Kouanfack, Charles | |
| Author | Ayouba, Ahidjo | |
| Author | Petoumenos, Kathy | |
| Author | Venter, W.D. Francois | |
| Author | Delaporte, Eric | |
| Author | Polizzotto, Mark N. | |
| Access date | 2025-03-19T16:46:40Z | |
| Available date | 2025-03-19T16:46:40Z | |
| Document date | 2025 | |
| Citation | PAPOT, Emmanuelle et al. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS, v. 39, n. 4, p. 448-456, Mar. 2025. | en_US |
| ISSN | 0269-9370 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/69101 | |
| Description | On behalf of COHIVE study group (COHIVE consortium includes ADVANCE, DolPHIN2, D2EFT and NAMSAL study groups). | en_US |
| Sponsorship | This work was supported by Unitaid [grant number 2016-09-UNSW]. Funding for ADVANCE is provided by ViiV Healthcare [study reference number: 207441] and Unitaid [grant number 2016-07-Wits RHI]. Funding for the D2 EFT study is provided by Unitaid [grant number: 2016-09-UNSW], National Health and Medical Research Council [grant number: APP1104610], ViiV Healthcare [ViiV Study reference number: 207460]. This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Disease (NIAID) under contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views and policies of the Department of Health and Human Services, nor does mention of the trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research has been funded in part by the National Institutes of Health (by NCI Contract No. HHSN261201500003I, Task Order No. HHSN26100013). The study drugs in D2 EFT (namely darunavir and dolutegravir) were donated by ViiV and Janssen. Funding for the NAMSAL-ANRS12313 study was provided by ANRSjEmerging Infectious Diseases [grant number: NAMSAL-ANRS-12313] and Unitaid [grant number: 2016-03-IBB]. Funding for DolPHIN2 study was provided by Unitaid, with dolutegravir donated by ViiV Healthcare. | en_US |
| Language | eng | en_US |
| Publisher | Lippincott Williams & Wilkins | en_US |
| Previous version | https://www.arca.fiocruz.br/handle/icict/68778 | en_US |
| Rights | open access | en_US |
| Title | SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa | en_US |
| Type | Article | en_US |
| DOI | 10.1097/QAD.0000000000004068 | |
| Abstract | Objective: Data on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies (ART) in HIV-1 infection to conduct a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey, between January and March 2021, while characterizing participants' features. Design: Cross-sectional serosurvey. Methods: Demographic characteristics, medical history and a serum sample were collected from consenting PWH. Samples were analyzed centrally for immunoglobulin G antibodies to recombinant nucleocapsid and spike proteins derived from SARS-CoV-2 using a Luminex based assay. Results: The 549 participants recruited in 9 sites across Africa had a median age of 40 years (interquartile range, IQR [34-45]); 63.0% (346) were female. All were on ART; 81.8% (449) had an HIV-1 viral load <50 copies/ml, with CD4 + cell count median at 478/mm 3 (IQR [320-677]). None had received vaccination against SARS-CoV-2. Forty participants (7.3%) had a prior SARS-CoV-2 PCR testing, of whom 10 were positive (1.8%). Crude SARS-CoV-2 seroprevalence was 36.2% (95% confidence interval (CI) [32.2-40.4]). In the explorative multivariable analysis, comparison of the characteristics of PWH with a positive SARS-CoV-2 serology with those with a negative or indeterminate serology: PWH with a body mass index (BMI) ≥30 kg/m 2 were more likely to have a positive serology than those with a BMI <25 (adjusted odds ratio (aOR) = 2.39 [1.48-3.86], P < 0.001); and PWH living in Cameroon were less likely to have a positive serology. Conclusion: This study demonstrates a substantial seroprevalence level of SARS-CoV-2 in PWH in the first quarter of 2021, with a marked disparity with the number of COVID-19 PCR tests reported positive. | en_US |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | en_US |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | en_US |
| Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Ezintsha. Johannesburg, South Africa. | en_US |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | en_US |
| Affilliation | Institute of Human Virology Nigeria. Abuja, Nigeria. | en_US |
| Affilliation | University of Zimbabwe Clinical Research Centre. Harare, Zimbabwe. | en_US |
| Affilliation | Desmond Tutu Health Foundation. Cape Town, South Africa. | en_US |
| Affilliation | The HIV Netherlands Australia Thailand Research Collaboration. Thai Red Cross AIDS Research Centre. Bangkok, Thailand. | en_US |
| Affilliation | University of Malaya. Faculty of Medicine. Department of Medicine. Infectious Diseases Unit. Kuala Lumpur, Malaysia. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Chennai Antiviral Research and Treatment Clinical Research Site. Infectious Diseases Medical Centre. Voluntary Health Services. Chennai, India. | en_US |
| Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Ezintsha. Johannesburg, South Africa. | en_US |
| Affilliation | Military Hospital Region N°1. Yaoundé, Cameroon. | en_US |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | en_US |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | en_US |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | en_US |
| Affilliation | Coordinación en Investigación Clínica Académica en Latinoamérica Fundación IBIS. Buenos Aires, Argentina. | en_US |
| Affilliation | Department of Molecular and Clinical Pharmacology University of Liverpool. Liverpool, UK. | en_US |
| Affilliation | Geneva University Hospitals. HIV/AIDS Unit Director. Geneva, Switzerland. | en_US |
| Affilliation | Central Hospital of Yaoundé. Yaoundé, Cameroon. | en_US |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | en_US |
| Affilliation | University of New South Wales. The Kirby Institute. Biostatistics and Databases Program. Sydney, NSW, Australia. | en_US |
| Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Ezintsha. Johannesburg, South Africa. | en_US |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | en_US |
| Affilliation | University of New South Wales. The Kirby Institute. Therapeutic and Vaccine Research Program. Sydney, NSW, Australia / The Australian National University. College of Health and Medicine. Clinical Hub for Interventional Research. Australia. | en_US |
| Subject | Coronavirus disease 2019 | en_US |
| Subject | People with HIV | en_US |
| Subject | Randomized clinical trials | en_US |
| Subject | Serology | en_US |
| e-ISSN | 1473-5571 | |
